The case for allowing performance-enhancing drugs in sports rests on three core arguments: the current ban doesn’t work, natural genetic advantages already create an uneven playing field, and prohibition pushes athletes toward dangerous black-market substances instead of medically supervised use. None of these points are fringe ideas. They come from bioethicists, sports scientists, and even admissions within the anti-doping system itself.
The Anti-Doping System Isn’t Working
The global anti-doping system, overseen by the World Anti-Doping Agency (WADA), costs at least $228 million per year, mostly spent performing roughly 270,000 drug tests annually. Despite that investment, WADA itself has acknowledged that “testing has not proven to be particularly effective in detecting dopers/cheats.”
The gap between who uses and who gets caught is enormous. Anonymous surveys of elite athletes, designed to bypass the fear of punishment, have estimated that between 21% and 45% of competitors at major international events used a banned substance in the prior year. The range depends on the survey method and the event studied, but even the lowest estimate means roughly one in five elite athletes is doping undetected. The official positive-test rate at most competitions sits in the low single digits. That means the current system primarily catches careless or under-resourced athletes while well-funded programs evade detection, creating a playing field that rewards the quality of your doping program rather than eliminating doping altogether.
Genetics Already Tilt the Field
One of the strongest philosophical arguments for allowing PEDs is that “natural” competition has never been truly fair. Athletes are born with wildly different genetic blueprints, and some of those blueprints deliver advantages identical to what banned substances provide.
The most famous example is Finnish cross-country skier Eero Mäntyranta, who competed in four Winter Olympics between 1960 and 1972, winning seven medals. He carried a genetic mutation that gave him roughly 50% more red blood cells than his competitors. That’s the same effect athletes chase when they use EPO or blood doping, both of which are banned. Mäntyranta’s advantage was celebrated. An athlete who achieves the same result through a substance is punished.
Research has identified specific gene variants consistently linked to athletic performance. One variant of the ACE gene is associated with greater endurance and exercise efficiency, while a different version correlates with strength and power. Another gene, ACTN3, has a variant tied to explosive power. These aren’t rare curiosities. They’re distributed unevenly across populations, meaning some athletes start with a biological head start that no amount of training can replicate for a competitor who lacks it. As bioethicists at Monash University have put it: “There is no fairness in the distribution of genetic advantage. Why should these inequalities be preserved?”
The Harm Reduction Argument
Banning PEDs doesn’t stop athletes from using them. It stops them from using them safely. Because doping is criminalized in sport, athletes who choose to use substances often do so without medical oversight, relying on black-market products of unknown purity and dosing advice from coaches or underground networks rather than physicians.
A growing number of researchers advocate a harm reduction model similar to approaches used in other areas of public health. The core principles include educating athletes about side effects, limiting the doses and duration of use, and monitoring health closely through regular bloodwork and medical checkups. Non-medical androgen use (the most common category of PED) carries well-documented short-term side effects and likely long-term risks including cardiovascular disease and permanent hormonal disruption. But those risks escalate dramatically when use is unsupervised. A clinical trial called the HARNAS study is now formally testing whether a structured harm reduction protocol produces better health outcomes than the current approach, which effectively leaves athletes to manage their own use in secret.
Legalization with medical oversight wouldn’t eliminate risk, but it would shift the calculus. Athletes could be honest with their doctors, use pharmaceutical-grade substances at controlled doses, and receive monitoring for early warning signs of cardiovascular or hormonal problems.
Therapeutic Use Exemptions Blur the Line
The current system already allows some athletes to use banned substances through Therapeutic Use Exemptions, or TUEs. Between 3,500 and 4,000 TUEs are granted globally each year. At the Olympic and Paralympic Games, athletes compete with approved access to stimulants, glucocorticoids, narcotics, hormone modulators, and diuretics.
At the 2020 Tokyo Olympics, stimulants were the most common TUE-approved substance, present among 0.39% of competing athletes. At the Rio 2016 Games, glucocorticoids (powerful anti-inflammatory drugs that can aid recovery and reduce pain) topped the list at 0.50%. At the Paralympic Games, the numbers are higher across nearly every category, with narcotics approved for up to 1.6% of athletes at the 2022 Beijing Winter Paralympics.
The TUE system creates an uncomfortable gray area. An athlete with a diagnosis can legally use a substance that enhances performance, while an equally talented competitor without that diagnosis cannot. Critics argue this is a distinction based on paperwork, not biology, and that it undermines the moral clarity the ban is supposed to provide.
Gene Editing Makes Enforcement Harder
The challenge of enforcing a ban is about to get significantly worse. Gene editing technologies now make it theoretically possible to modify an athlete’s DNA to produce more red blood cells, build muscle more efficiently, or recover faster from injury. Unlike a substance you inject or swallow, a genetic edit becomes part of your biology. There’s no foreign chemical to detect in a urine or blood sample.
WADA is currently funding research to develop detection methods for gene doping, starting with animal models and working toward a tool that could screen 20 to 30 human genes linked to potential performance enhancement. But the project is in its early stages, and distinguishing an intentional edit from a naturally occurring genetic variation is a formidable technical problem. If the current system already struggles to catch athletes using conventional substances, the prospect of enforcing a ban against modifications written into an athlete’s own genome raises serious questions about whether prohibition remains viable as a long-term strategy.
What Legalization Could Look Like
Proponents of allowing PEDs don’t typically argue for a free-for-all. The most common proposal involves regulated access: athletes would use approved substances under medical supervision, with mandatory health monitoring, transparent disclosure, and enforced safety limits. Think of it less like removing all rules and more like replacing an unenforceable prohibition with a regulated system, similar to how many countries handle alcohol or contact sports like boxing and MMA, where the activity itself carries inherent risk but is managed rather than banned.
The argument also reframes what sport is supposed to test. If competition is meant to measure training, strategy, dedication, and execution, then removing the randomness of genetic advantage (or at least allowing athletes to compensate for it) could make results more reflective of effort and skill. If, on the other hand, sport is meant to celebrate natural human diversity, then the current system makes sense in principle, even if it fails in practice.
That tension sits at the heart of the debate. The case for legalization doesn’t require you to think PEDs are good. It requires you to weigh whether the current ban, with its massive costs, inconsistent enforcement, and unintended health consequences, is producing a result that’s actually better than the alternative.